Brind.

Merck & Co. and Verona Pharma are diversifying operations and expanding global clinical trial access ahead of the KEYTRUDA patent expiry.

1 report, 1 independent Updated Aug 28

AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Who's involved

What this event is mainly about

Merck KGaA Verona Pharma

Keep exploring

The entities involved

Merck KGaA
German multinational science and technology company
- MSD, which operates as Merck & Co. in the US and Canada, has appointed Vidhya as Associate Vice President.Mon 12:02
- Merck KGaA filed required 13F reports with the Securities and Exchange Commission regarding institutional holdings on June 15, 2026.Mon 02:05
Verona Pharma
company in London, United Kingdom

Nothing else this week.

Coverage

Newest first; wire copies grouped

Aug 28Insider MonkeyMerck & Co., Inc. (MRK) Expands Targeted Therapy Pipeline with ADC Advances We recently published 11 Best Cancer Stocks to Buy Right Now.Merck & Co., Inc. is one of them. Merck & Co., Inc. (NYSE:MRK)